Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • MedAdvisor (MDR) has fast-tracked the rollout of Phase 1 of its delivery service to help pharmacies and patients during the COVID-19 crisis
  • This home delivery service allows patients to order, pay for, and request delivery of their medications through the MedAdvisor App
  • Phase 2 of the delivery service will allow pharmacies to offer same-day delivery by using MedAdvisor’s delivery provider, Kings Transport
  • Rollout of this phase is planned to begin by mid-this year and will initially focus on major metropolitan centres
  • MedAdvisor is up a steady 24.2 per cent and shares are trading for 41 cents each

MedAdvisor (MDR) has fast-tracked the rollout of Phase 1 of its delivery service to help pharmacies and patients during the COVID-19 pandemic.

By fast-tracking the launch, MedAdvisor is helping relieve the pressure on pharmacies who are struggling to keep up with demand.

This home delivery service enable patients to order, pay for, and request delivery of their medications from the MedAdvisor App.

As part of the COVID-19 package, the Australian Federal Government has guaranteed $25 million to deliver much-needed medication to those at risk and unable to leave their homes.

Temporary measures have been put in place to provide non-contact delivery to avoid unnecessary contact with vulnerable patients.

Sourced: MedAdvisor

However, MedAdvisor is not changing the way medication is distributed as many pharmacies already offer some form of delivery to their customers.

MedAdvisor will allow pharmacies to use their own service, usually pharmacy staff, or MedAdvisor’s own delivery partner.

Announced on November 1, Phase 2 of the delivery service will allow pharmacies to offer same-day delivery by using MedAdvisor’s deliver provider, Kings Transport.

Rollout of Phase 2 is planned to begin in the second half of the 2020 financial year and will first focus on major metropolitan centres.

“MedAdvisor is playing a critical role in remote medicines management in Australia during this health crisis,” CEO Robert Read said.

“Our tools allow patients to track, manage and order their medications whilst at home. Now with the ability to pay in advance and request delivery from your pharmacy, it can streamline the workflow for community pharmacies when managing patients remotely,” he added.

MedAdvisor is up a steady 24.2 per cent on the market and shares are trading for 41 cents each at 2:23 pm AEDT.

MDR by the numbers
More From The Market Herald
Rhythm Biosciences (ASX:RHY) - Chairman, Otto Buttula

" Rhythm Biosciences (ASX:RHY) nears ColoSTAT commercialisation

Cancer diagnostics technology company Rhythm Biosciences (RHY) has updated the market regarding the commercialisation of ColoSTAT.

" Epsilon (ASX:EPN) signs manufacturing agreement for Jamaican cannabis

Epsilon Healthcare (EPN) has signed a long term manufacturing agreement for Cannim’s Jamaican cannabis products.
Suda Pharmaceuticals (ASX:SUD) - CEO and MD, Michael Baker

" SUDA Pharmaceuticals (ASX:SUD) has insomnia treatment approved in Chile

SUDA Pharmaceuticals (SUD) has had its lead product, ZolpiMist, for short-term insomnia in adults, approved by the Chile Ministry of Health.
Dimerix (ASX:DXB) - Managing Director & CEO, Dr Nina Webster

" Dimerix (ASX:DXB) receives approvals to start Phase 3 kidney damage trial

Dimerix (DXB) has been granted Australian ethics and regulatory approval for its Phase 3 clinical trial in FSGS kidney patients.